Jones Financial Companies Lllp Gain Therapeutics, Inc. Transaction History
Jones Financial Companies Lllp
- $111 Billion
- Q1 2025
A detailed history of Jones Financial Companies Lllp transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Jones Financial Companies Lllp holds 427,700 shares of GANX stock, worth $718,536. This represents 0.0% of its overall portfolio holdings.
Number of Shares
427,700
Previous 1,416
30104.8%
Holding current value
$718,536
Previous $2,000
40700.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.52MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$988,5280.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$951,0980.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$474,1140.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$428,3830.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$329,3230.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...